{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04176198",
            "orgStudyIdInfo": {
                "id": "BBI-TP-3654-102"
            },
            "organization": {
                "fullName": "Sumitomo Pharma America, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of Oral TP-3654 in Patients With Myelofibrosis",
            "officialTitle": "A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-of-oral-tp-in-patients-with-myelofibrosis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-12-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-04-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2030-04-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-11-08",
            "studyFirstSubmitQcDate": "2019-11-22",
            "studyFirstPostDateStruct": {
                "date": "2019-11-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-30",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sumitomo Pharma America, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of TP-3654 in patients with intermediate or high-risk primary or secondary MF.",
            "detailedDescription": "Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive ruxolitinib or fedratinib.\n\nArm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.\n\nArm 3 will enroll patients who have been previously treated on JAK inhibitor (except momelotinib) that was complicated by anemia, thrombocytopenia or hematoma."
        },
        "conditionsModule": {
            "conditions": [
                "Myelofibrosis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 240,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm 1: TP-3654",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: TP-3654"
                    ]
                },
                {
                    "label": "Arm 2: TP-3654 added on to ruxolitinib",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: TP-3654",
                        "Drug: Ruxolitinib"
                    ]
                },
                {
                    "label": "Arm 3: TP-3654 in combination with momelotinib",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: TP-3654",
                        "Drug: Momelotinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "TP-3654",
                    "description": "Oral PIM Inhibitor",
                    "armGroupLabels": [
                        "Arm 1: TP-3654",
                        "Arm 2: TP-3654 added on to ruxolitinib",
                        "Arm 3: TP-3654 in combination with momelotinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ruxolitinib",
                    "description": "Oral JAK inhibitor",
                    "armGroupLabels": [
                        "Arm 2: TP-3654 added on to ruxolitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Momelotinib",
                    "description": "Oral JAK inhibitor",
                    "armGroupLabels": [
                        "Arm 3: TP-3654 in combination with momelotinib"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Determine the incidence of dose-limiting toxicities (DLTs)",
                    "description": "Number of participants with DLTs",
                    "timeFrame": "28 days"
                },
                {
                    "measure": "Determine the incidence of treatment emergent adverse events",
                    "description": "Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events",
                    "timeFrame": "From start of treatment to end of study"
                },
                {
                    "measure": "Assess patients for any evidence of preliminary activity by determining the number of patients with \u2265 35% spleen volume reduction (SVR35)",
                    "description": "Number of participants with \u2265 35% spleen volume reduction (SVR35)",
                    "timeFrame": "From start of treatment to end of study"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of participants achieving objective response by IWG-MRT response criteria",
                    "description": "Number of participants achieving complete remission, partial remission, clinical improvement, progressive disease and stable disease.",
                    "timeFrame": "From start of treatment to end of study"
                },
                {
                    "measure": "Number of participants who have \u2265 25% spleen volume reduction",
                    "description": "Number of participants who have \u2265 25% spleen volume reduction compared to baseline",
                    "timeFrame": "Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment."
                },
                {
                    "measure": "Number of participants with \u2265 50% improvement in total symptom score (TSS50) at week 24",
                    "description": "Number of participants who have \u2265 50% total symptom score reduction by MFSAF compared to baseline after 24 weeks of treatment.",
                    "timeFrame": "24 weeks"
                },
                {
                    "measure": "Determine the change in Patient Global Impression of Change (PGIC) at week 24 through end of study.",
                    "description": "Change in PGIC score",
                    "timeFrame": "After 24 weeks of treatment to end of study"
                },
                {
                    "measure": "Determine the incidence of QT interval changes",
                    "description": "Changes in QT interval and heart rhythm",
                    "timeFrame": "25 hours"
                },
                {
                    "measure": "Establish the half-life (t\u00bd) of TP-3654 monotherapy, in combination with ruxolitinib, and in combination with momelotinib",
                    "description": "The estimate of time for the TP-3654 concentration or amount to be reduced by half",
                    "timeFrame": "24 hours"
                },
                {
                    "measure": "Establish the Peak Plasma Concentration (Cmax) of TP-3654 monotherapy, in combination with ruxolitinib, and in combination with momelotinib",
                    "description": "The maximum TP-3654 concentration after administration",
                    "timeFrame": "24 hours"
                },
                {
                    "measure": "Establish the Time of Maximum concentration observed (tmax) of TP-3654 monotherapy, in combination with ruxolitinib, and in combination with momelotinib",
                    "description": "The time to reach maximum TP-3654 concentration",
                    "timeFrame": "24 hours"
                },
                {
                    "measure": "Establish the Area under the plasma concentration versus time curve (AUC) of TP-3654 monotherapy, in combination with ruxolitinib, and in combination with momelotinib",
                    "description": "The amount of drug exposure over 24 hours period after administration",
                    "timeFrame": "24 hours"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Study potential pharmacodynamic (PD) markers of TP-3654",
                    "description": "Evaluate exploratory biomarkers, including change in protein phosphorylation and inflammatory cytokines, in peripheral blood samples and bone marrow biopsy samples.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Number of patients with reduction in bone marrow fibrosis",
                    "timeFrame": "Every 24 weeks to end of study"
                },
                {
                    "measure": "TP-3654 monotherapy: Changes in platelet count over time in patients with baseline platelet count < 100",
                    "timeFrame": "From start of treatment to end of study"
                },
                {
                    "measure": "TP-3654 combination arms: Assess the increase in hemoglobin \u22651.5 or \u2265 2 g/dL from baseline",
                    "timeFrame": "From start of treatment to end of study"
                },
                {
                    "measure": "TP-3654 combination arms: Assess red blood cell transfusion independence status or any requirement change",
                    "timeFrame": "From start of treatment to end of study"
                },
                {
                    "measure": "Establish overall survival",
                    "description": "The time interval from treatment start date of death from any cause",
                    "timeFrame": "From start of treatment to end of study"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Patients must meet all of the following inclusion criteria to be eligible:\n\nTP-3654 Monotherapy Arm:\n\n* Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF as per WHO diagnostic criteria and intermediate or high-risk primary or secondary MF based on the Dynamic International Prognostic Scoring System (DIPSS)\n* Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor.\n* Fulfill the following laboratory parameters:\n\n  * Platelet count \u2265 25 X 10\\^9 /L, without the assistance of growth factors or platelet transfusions\n  * Absolute Neutrophil Count (ANC) \u2265 1 x 10\\^9/L without the assistance of granulocyte growth factors\n  * Peripheral blood blast count \\< 5%\n  * Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1\n  * Life expectancy \u2265 6 months\n  * Adequate renal function, as determined by clinical laboratory tests (serum creatinine \u2264 1.5 x upper limit of normal (ULN), or calculated creatinine clearance \u2265 30 mL/min) (Cockcroft-Gault)\n  * Adequate hepatic function: ALT and AST \u2264 3 \u00d7 ULN (ALT and AST \u2264 5 \u00d7 ULN if liver involvement secondary to MF); direct bilirubin \u2264 2 \u00d7 ULN\n  * Adequate coagulation function: PT and PTT \u2264 1.5 \u00d7 ULN; INR \u2264 1.2 \u00d7 ULN (INR \\< 2.5 x ULN permitted if on chronic anticoagulant therapy)\n  * Splenomegaly defined as splenic length \u2265 5 cm below the costal margin by palpation or spleen volume of \u2265 450 cm3 by Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT) scan, within 2 weeks prior to Cycle 1 Day 1.\n  * Dose escalation: At least 2 symptoms measurable (score \u2265 1) using the MF-SAF, v4.0.\n  * Dose expansion: At least 2 symptoms measureable with each score of \u2265 3 or a total average score of \u2265 10 per MFSAF, v4.0.\n\nTP-3654 + Ruxolitinib Arm:\n\n* Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF as per WHO diagnostic criteria, and intermediate or high-risk primary or secondary MF based on the DIPSS\n* Has been on ruxolitinib treatment for \u2265 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for \u2265 8 weeks prior to the first dose of TP-3654, but has either lost response or had a suboptimal or plateau in response\n* Fulfills the following laboratory parameters:\n\n  * Platelet count \u2265 50 \u00d7 10\\^9/L (without the assistance of growth factors or platelet transfusions)\n  * ANC \u2265 1 \u00d7 109/L without the assistance of granulocyte growth factors\n  * Peripheral blood blast count \\< 5% at screening\n  * Adequate renal function, as determined by clinical laboratory tests: serum creatinine \u2264 1.5 \u00d7 ULN or calculated creatinine clearance \u2265 30 mL/min (using Cockcroft-Gault formula)\n  * Adequate hepatic function: ALT and AST \u2264 3 \u00d7 ULN (ALT and AST \u2264 5 \u00d7 ULN if liver involvement secondary to MF); direct bilirubin \u2264 2 \u00d7 ULN\n  * Adequate coagulation function: PT and PTT \u2264 1.5 \u00d7 ULN; INR \u2264 1.2 \u00d7 ULN (INR \\< 2.5 x ULN permitted if on chronic anticoagulant therapy)\n  * Splenomegaly, defined as splenic length \u2265 5 cm below the costal margin by palpation or spleen volume of \u2265 450 cm3 by MRI/CT scan, within 2 weeks prior to Cycle 1 Day 1\n  * At least 2 symptoms measurable with each score \u2265 3 or a total average score of \u2265 10 per MFSAF v4.0\n  * ECOG performance status \u2264 1\n  * Life expectancy \u2265 6 months\n\nTP-3654 + Momelotinib Arm\n\n* Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF as per WHO diagnostic criteria, and intermediate or high-risk primary or secondary MF based on the DIPSS\n* Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for \u2265 12 weeks, or \u2265 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of \u2265 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma\n* Fulfills the following laboratory parameters:\n* Anemic, defined as Hb \\<10 g/dL or requiring RBC transfusion at baseline\n* Platelet count \u2265 50 \u00d7 109/L (without the assistance of growth factors or platelet transfusions)\n* ANC \u2265 1 \u00d7 109/L without the assistance of granulocyte growth factors\n* Peripheral blood blast count \\< 5% at screening\n* Adequate renal function, as determined by clinical laboratory tests: serum creatinine \u2264 1.5 \u00d7 ULN or calculated creatinine clearance \u2265 30 mL/min (using Cockcroft-Gault formula)\n\n  * Adequate hepatic function: ALT and AST \u2264 3 \u00d7 ULN (ALT and AST \u2264 5 \u00d7 ULN if there is liver involvement secondary to MF); direct bilirubin \u2264 2 \u00d7 ULN\n  * Adequate coagulation function: PT and PTT \u2264 1.5 \u00d7 ULN; INR \u2264 1.2 \u00d7 ULN (INR \\< 2.5 \u00d7 ULN permitted if on chronic anticoagulant therapy)\n  * Splenomegaly, defined as splenic length \u2265 5 cm below the costal margin by palpation or spleen volume of \u2265 450 cm3 by MRI/CT scan within 2 weeks prior to Cycle 1 Day 1\n  * At least 2 symptoms measurable with each score of \u2265 3 or a total average score of \u2265 10 per MFSAF v4.0\n  * ECOG performance status \u2264 1\n  * Life expectancy \u2265 6 months\n\nPatients meeting any one of these exclusion criteria will be prohibited from participating in this study:\n\nTP-3654 Monotherapy Arm:\n\n* Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1.\n* Major surgery within 2 weeks before the first dose of either study drug.\n* Splenic irradiation within 6 months prior to Screening or prior splenectomy.\n* Prior allogeneic stem cell transplant within the last 6 months.\n* Eligible for allogeneic bone marrow or stem cell transplantation.\n* Unresolved Grade \u2265 2 non-hematological toxicity related to prior treatment\n* History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF)\\< 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.\n* Corrected QT interval (using Fridericia's correction formula) of \\> 480 msec.\n* Prior or concurrent malignancy whose natural history or treatment would have a significant potential to interfere with the safety or efficacy assessments of the investigational regime.\n* Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.\n* Experienced portal hypertension or any of its complications.\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.\n* Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)\n* Exhibited allergic reactions or sensitivity to TP-3654, or any structurally similar compound, biological agent, or to any component of the formulation.\n* Medical condition or gastrointestinal (GI) tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.\n* Used hydroxyurea or anagrelide within 24 hours prior to the first dose.\n* Systemic steroid therapy (\\>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).\n\nTP-3654 + Ruxolitinib Arm:\n\n* Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).\n* Received systemic steroid therapy (\\>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)\n* Currently receiving treatment with a prohibited medication that cannot be discontinued at least 1 week prior to Cycle 1 Day 1 (Section 6.9.1)\n* Known allergic reactions or sensitivity to TP-3654, any structurally similar drug, or to any component of the formulation\n* Splenic irradiation within 6 months prior to Screening or prior splenectomy\n* Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).\n* Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible._\n* Major surgery within 2 weeks prior to Cycle 1 Day 1\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1\n* Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)\n* Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).\n* Unresolved Grade \u2265 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)\n* History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF \\< 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1\n* Corrected QTcF of \\> 480 msec\n* Prior or concurrent malignancy whose natural history or treatment has a significant potential to interfere with the safety or efficacy assessment of the study intervention\n* History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea\n* Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding\n\nTP-3654 + Momelotinib Arm:\n\n* Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib is not allowed, in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper, hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).\n* Received systemic steroid therapy (\\>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).\n* Currently receiving treatment with a prohibited medication that cannot be discontinued at least 1 week prior to Cycle 1 Day 1\n* Known allergic reactions or sensitivity to TP-3654, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention\n* Splenic irradiation within 6 months prior to screening or prior splenectomy\n* Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).\n* Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).\n* Major surgery within 2 weeks prior to Cycle 1 Day 1\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1\n* Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)\n* Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)\n* Unresolved Grade \u2265 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)\n* Presence of Grade \u2265 2 peripheral neuropathy\n* History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF \\< 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1\n* Corrected QTcF of \\> 480 msec\n* Prior or concurrent malignancy whose natural history or treatment has a significant potential to interfere with the safety or efficacy assessment of the study intervention\n* History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea\n* Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Reyna Bishop",
                    "role": "CONTACT",
                    "phone": "617-674-6800",
                    "email": "reyna.bishop@us.sumitomo-pharma.com"
                },
                {
                    "name": "Tomoko Kuwabara",
                    "role": "CONTACT",
                    "email": "tomoko.kuwabara@us.sumitomo-pharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of Alabama",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35294",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tiffany Hill",
                            "role": "CONTACT",
                            "phone": "205-934-9591"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "The University of Arizona Cancer Center",
                    "status": "RECRUITING",
                    "city": "Tucson",
                    "state": "Arizona",
                    "zip": "85724",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Audrey Johnson",
                            "role": "CONTACT",
                            "phone": "520-694-9084",
                            "email": "audieejayy@arizona.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.22174,
                        "lon": -110.92648
                    }
                },
                {
                    "facility": "City of Hope",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Michelle Velasquez",
                            "role": "CONTACT",
                            "phone": "626-218-3524",
                            "email": "mvelaszuez@coh.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "University of Southern California",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90033",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shirley Sian",
                            "role": "CONTACT",
                            "phone": "323-865-0456",
                            "email": "sian_s@med.usc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Hoag Family Cancer Institute",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Newport Beach",
                    "state": "California",
                    "zip": "92663",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.61891,
                        "lon": -117.92895
                    }
                },
                {
                    "facility": "Blood Cancer Center",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Brooke Rhodes",
                            "role": "CONTACT",
                            "email": "Brookerhodes@sarahcannon.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "University of Florida Health Shands Cancer Hospital",
                    "status": "COMPLETED",
                    "city": "Gainesville",
                    "state": "Florida",
                    "zip": "32608",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.65163,
                        "lon": -82.32483
                    }
                },
                {
                    "facility": "University of Miami",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alessia Zoso",
                            "role": "CONTACT",
                            "phone": "305-243-0327",
                            "email": "azoso@miami.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Emory University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "University of Chicago",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60637",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Howie Weiner",
                            "role": "CONTACT",
                            "email": "HWeiner@bsd.uchicago.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "University of Michigan",
                    "status": "RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "48109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kelsey Bolin",
                            "role": "CONTACT",
                            "phone": "734-936-2193",
                            "email": "kntillma@med.umich.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                },
                {
                    "facility": "Washington University of Medicine",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nicole Gaudin",
                            "role": "CONTACT",
                            "phone": "314-747-7960",
                            "email": "nrgaudin@wustl.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "John Theurer Cancer Center at Hackensack University Medical Center",
                    "status": "RECRUITING",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jason Brecher",
                            "role": "CONTACT",
                            "phone": "551-966-5274",
                            "email": "jason.brecher@hmhn.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                },
                {
                    "facility": "Roswell Park Comprehensive Cancer Center",
                    "status": "COMPLETED",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14263",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                },
                {
                    "facility": "Icahn School of Medicine at Mount Sinai",
                    "status": "NOT_YET_RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mikaela Dougherty",
                            "role": "CONTACT",
                            "email": "Mikaela.dougherty@mssm.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Weill Cornell Medical Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Penina Steward",
                            "role": "CONTACT",
                            "phone": "212-746-1858",
                            "email": "pes4006@med.cornell.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Duke Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ben Dosan",
                            "role": "CONTACT",
                            "email": "benjamin.dosan@duke.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "Ohio State University",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43210",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Molly Brandenburg",
                            "role": "CONTACT",
                            "phone": "614-366-7951",
                            "email": "Molly.Brandenburg@osumc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "Tri-Star Centennial Medical Center",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Brooke Rhodes",
                            "role": "CONTACT",
                            "email": "brooke.rhodes@sarahcannon.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Vanderbilt University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37232",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77054",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kurt Schroeder",
                            "role": "CONTACT",
                            "phone": "713-745-2232",
                            "email": "kdschroe@mdanderson.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Huntsman Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Emerson Lebleu",
                            "role": "CONTACT",
                            "phone": "801-587-9703"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "University of Virginia Cancer Center",
                    "status": "RECRUITING",
                    "city": "Charlottesville",
                    "state": "Virginia",
                    "zip": "22903",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kelly Reed",
                            "role": "CONTACT",
                            "phone": "434-297-7783",
                            "email": "yvy8ge@hscmail.mcc.virginia.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.02931,
                        "lon": -78.47668
                    }
                },
                {
                    "facility": "University of Washington - Fred Hutchinson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anna Halpern",
                            "role": "CONTACT",
                            "email": "halpern2@uw.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                },
                {
                    "facility": "Royal Adelaide Hospital",
                    "status": "RECRUITING",
                    "city": "Adelaide",
                    "state": "South Australia",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Christine Hoare",
                            "role": "CONTACT",
                            "email": "christine.hoare@sa.gov.au"
                        }
                    ],
                    "geoPoint": {
                        "lat": -34.92866,
                        "lon": 138.59863
                    }
                },
                {
                    "facility": "Eastern Health Box Hill Hospital",
                    "status": "RECRUITING",
                    "city": "Box Hill",
                    "state": "Victoria",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": -37.81887,
                        "lon": 145.12545
                    }
                },
                {
                    "facility": "Icon Cancer Centre (Ashford Cancer Centre Research)",
                    "status": "RECRUITING",
                    "city": "Adelaide",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Stanley Cheung, MD",
                            "role": "CONTACT",
                            "email": "Stanley.Cheung@icon.team"
                        }
                    ],
                    "geoPoint": {
                        "lat": -34.92866,
                        "lon": 138.59863
                    }
                },
                {
                    "facility": "University Hospitals Leuven",
                    "status": "RECRUITING",
                    "city": "Leuven",
                    "state": "Vlaams-Brabant",
                    "zip": "3000",
                    "country": "Belgium",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.87959,
                        "lon": 4.70093
                    }
                },
                {
                    "facility": "ZNA Cadix",
                    "status": "RECRUITING",
                    "city": "Antwerp",
                    "zip": "2020",
                    "country": "Belgium",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.21989,
                        "lon": 4.40346
                    }
                },
                {
                    "facility": "ZNA Middelheim",
                    "status": "RECRUITING",
                    "city": "Antwerp",
                    "zip": "2030",
                    "country": "Belgium",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.21989,
                        "lon": 4.40346
                    }
                },
                {
                    "facility": "Centre Hospitalier Universitaire D'Amiens",
                    "status": "RECRUITING",
                    "city": "Amiens",
                    "zip": "80054",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 49.9,
                        "lon": 2.3
                    }
                },
                {
                    "facility": "Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet",
                    "status": "RECRUITING",
                    "city": "Nice",
                    "zip": "06200",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.70313,
                        "lon": 7.26608
                    }
                },
                {
                    "facility": "Hospital Saint Louis",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "zip": "75010",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "Institut Gustave Roussy",
                    "status": "RECRUITING",
                    "city": "Villejuif",
                    "zip": "94805",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.7939,
                        "lon": 2.35992
                    }
                },
                {
                    "facility": "IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed Ematologiche - UO Ematologia",
                    "status": "RECRUITING",
                    "city": "Bologna",
                    "zip": "40138",
                    "country": "Italy",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.49381,
                        "lon": 11.33875
                    }
                },
                {
                    "facility": "IRCCS istituto Romagnolo per lo studio dei tumori \"Dino Amadori\"",
                    "status": "RECRUITING",
                    "city": "Meldola",
                    "zip": "47014",
                    "country": "Italy",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.12775,
                        "lon": 12.0626
                    }
                },
                {
                    "facility": "Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico",
                    "status": "RECRUITING",
                    "city": "Milan",
                    "zip": "20122",
                    "country": "Italy",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.46427,
                        "lon": 9.18951
                    }
                },
                {
                    "facility": "Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino",
                    "status": "RECRUITING",
                    "city": "Torino",
                    "zip": "10126",
                    "country": "Italy",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.07049,
                        "lon": 7.68682
                    }
                },
                {
                    "facility": "Aichi Medical University Hospital",
                    "status": "RECRUITING",
                    "city": "Aichi",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Akiyoshi Takami",
                            "role": "CONTACT",
                            "phone": "0561-62-3311",
                            "email": "takami.akiyoshi.490@mail.aichi-med-u.ac.jp"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.51879,
                        "lon": 130.62158
                    }
                },
                {
                    "facility": "National Cancer Center Hospital East",
                    "status": "RECRUITING",
                    "city": "Chiba",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Junichiro Yuda, MD",
                            "role": "CONTACT",
                            "phone": "04-7133-1111",
                            "email": "jyuda@east.ncc.go.jp"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.6,
                        "lon": 140.11667
                    }
                },
                {
                    "facility": "Kyushu University Hospital",
                    "status": "RECRUITING",
                    "city": "Fukuoka",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Takuji Yamauchi, MD",
                            "role": "CONTACT",
                            "phone": "092-641-1151",
                            "email": "yamauchi.takuji.355@m.kyushu-u.ac.jp"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.6,
                        "lon": 130.41667
                    }
                },
                {
                    "facility": "University of Miyazaki Hospital",
                    "status": "RECRUITING",
                    "city": "Miyazaki",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Kazuya Shimoda, MD",
                            "role": "CONTACT",
                            "phone": "0985-85-1510",
                            "email": "kshimoda@med.miyazaki-u.ac.jp"
                        }
                    ],
                    "geoPoint": {
                        "lat": 31.91667,
                        "lon": 131.41667
                    }
                },
                {
                    "facility": "Okayama University Hospital",
                    "status": "RECRUITING",
                    "city": "Okayama",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.65,
                        "lon": 133.93333
                    }
                },
                {
                    "facility": "Osaka University Hospital",
                    "status": "RECRUITING",
                    "city": "Osaka",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Michiko Ichii, MD",
                            "role": "CONTACT",
                            "phone": "06-6879-5111"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.69374,
                        "lon": 135.50218
                    }
                },
                {
                    "facility": "Saitama Medical Center",
                    "status": "RECRUITING",
                    "city": "Saitama",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Takayuki Tabayashi",
                            "role": "CONTACT",
                            "phone": "049-228-3411",
                            "email": "ttabaya@saitama-med.ac.jp"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.90807,
                        "lon": 139.65657
                    }
                },
                {
                    "facility": "Tohoku University Hospital",
                    "status": "RECRUITING",
                    "city": "Sendai",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Yasushi Onishi, MD",
                            "role": "CONTACT",
                            "phone": "022-717-7000",
                            "email": "yonishi@med.tohoku.ac.jp"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.26667,
                        "lon": 140.86667
                    }
                },
                {
                    "facility": "Shizuoka Cancer Center",
                    "status": "RECRUITING",
                    "city": "Shizuoka",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Masafumi Fukaya, MD",
                            "role": "CONTACT",
                            "phone": "055-989-5222",
                            "email": "m.fukaya@scchr.jp"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.98333,
                        "lon": 138.38333
                    }
                },
                {
                    "facility": "Juntendo University Hospital",
                    "status": "RECRUITING",
                    "city": "Tokyo",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Shuichi Shirane, MD",
                            "role": "CONTACT",
                            "phone": "03-3813-3111",
                            "email": "sshirane@juntendo.ac.jp"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.6895,
                        "lon": 139.69171
                    }
                },
                {
                    "facility": "United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital",
                    "status": "RECRUITING",
                    "city": "Lincoln",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.22683,
                        "lon": -0.53792
                    }
                },
                {
                    "facility": "University College London Hospital's NHS foundation Trust",
                    "status": "RECRUITING",
                    "city": "London",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "SMPA Investigative Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000055728",
                    "term": "Primary Myelofibrosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009196",
                    "term": "Myeloproliferative Disorders"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M28312",
                    "name": "Primary Myelofibrosis",
                    "asFound": "Myelofibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12149",
                    "name": "Myeloproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4705",
                    "name": "Primary Myelofibrosis",
                    "asFound": "Myelofibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1311",
                    "name": "Chronic Myeloproliferative Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000546012",
                    "term": "N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1474",
                    "name": "Janus Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M256030",
                    "name": "N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide",
                    "asFound": "Expression levels",
                    "relevance": "HIGH"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}